Karyopharm Therapeutics Inc (KPTI) Can’t Be More Safe. Trades Significantly Higher

September 17, 2017 - By Adrian Mccoy

Investors sentiment increased to 2.4 in 2016 Q4. Its up 0.88, from 1.52 in 2016Q3. It increased, as 5 investors sold Karyopharm Therapeutics Inc shares while 15 reduced holdings. 14 funds opened positions while 34 raised stakes. 24.99 million shares or 9.31% more from 22.86 million shares in 2016Q3 were reported.
Blackrock Fund invested in 1.38M shares or 0% of the stock. D E Shaw & Communications owns 0% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI) for 41,270 shares. Price T Rowe Assocs Inc Md holds 0% or 13,874 shares. 10,564 are owned by Voya Investment Mngmt Lc. Jacobs Levy Equity Mngmt reported 43,600 shares. Metropolitan Life Insur has 21,911 shares for 0% of their portfolio. Deutsche Comml Bank Ag holds 118,466 shares. Piermont Cap Mngmt holds 0.11% or 51,080 shares. 55,844 were accumulated by California State Teachers Retirement Systems. Royal National Bank & Trust Of Canada has 0% invested in Karyopharm Therapeutics Inc (NASDAQ:KPTI). New York-based Jpmorgan Chase And has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Millennium Lc owns 711,156 shares. Utd Serv Automobile Association holds 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI) or 75,900 shares. 216,990 are owned by Baker Bros Advisors Lp. Endurance Wealth invested in 16,000 shares.

The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) is a huge mover today! The stock increased 4.07% or $0.43 on September 15, reaching $11. About 432,710 shares traded or 146.40% up from the average. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has risen 21.19% since September 17, 2016 and is uptrending. It has outperformed by 4.49% the S&P500.
The move comes after 7 months positive chart setup for the $518.53M company. It was reported on Sep, 17 by Barchart.com. We have $11.99 PT which if reached, will make NASDAQ:KPTI worth $46.67 million more.

Analysts expect Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report $-0.64 EPS on November, 6.They anticipate $0.05 EPS change or 7.25 % from last quarter’s $-0.69 EPS. After having $-0.64 EPS previously, Karyopharm Therapeutics Inc’s analysts see 0.00 % EPS growth.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Ratings Coverage

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. had 22 analyst reports since August 11, 2015 according to SRatingsIntel. Robert W. Baird initiated the stock with “Outperform” rating in Tuesday, June 28 report. Leerink Swann maintained the shares of KPTI in report on Tuesday, August 11 with “Outperform” rating. As per Tuesday, March 15, the company rating was downgraded by Bank of America. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) earned “Buy” rating by Jefferies on Monday, September 11. The firm earned “Hold” rating on Tuesday, March 15 by Jefferies. The firm has “Buy” rating by H.C. Wainwright given on Thursday, September 8. Jefferies downgraded the shares of KPTI in report on Wednesday, January 6 to “Hold” rating. The stock has “Buy” rating by Cantor Fitzgerald on Friday, June 23. The rating was initiated by Jefferies on Wednesday, September 9 with “Buy”. On Wednesday, August 12 the stock rating was maintained by MLV with “Buy”.

More notable recent Karyopharm Therapeutics Inc (NASDAQ:KPTI) news were published by: Seekingalpha.com which released: “Karyopharm’s Selinexor Should Drive Substantial Growth” on March 27, 2017, also Seekingalpha.com with their article: “Karyopharm Therapeutics: Buy, Sell, Or Hold?” published on June 30, 2017, Streetinsider.com published: “Karyopharm Therapeutics (KPTI) Presents Selinexor and KPT-9274 Clinical Data …” on September 08, 2017. More interesting news about Karyopharm Therapeutics Inc (NASDAQ:KPTI) were released by: Seekingalpha.com and their article: “Karyopharm Therapeutics’ (KPTI) CEO Michael Kauffman on Q2 2017 Results …” published on August 08, 2017 as well as Globenewswire.com‘s news article titled: “US FDA Division of Hematology Products Lifts Partial Clinical Hold on …” with publication date: March 30, 2017.

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The company has market cap of $518.53 million. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It currently has negative earnings. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export compounds that inhibit the nuclear export protein, XPO1.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.